Blue Cross highlights medical, benefit policy changes

NEW PAYABLE PROCEDURES

Early detection of prostate cancer: Biomarkers

For the purpose of early detection of prostate cancer, testing of genetic and protein biomarkers prior to an initial or repeat biopsy is considered established when criteria are met.

Procedure codes *0005U and *0113U were added as payable for all groups, effective July 1, 2022.